期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 105, 期 11, 页码 4277-4282出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0708647105
关键词
peroxisome proliferator-activated receptor delta; vascular inflammation; macrophage
资金
- Howard Hughes Medical Institute Funding Source: Medline
- NHLBI NIH HHS [P01 HL088093, R01 HL105278] Funding Source: Medline
- NIDDK NIH HHS [R37 DK057978] Funding Source: Medline
Activation of the nuclear hormone receptor peroxisome proliferator-activated receptor delta (PPAR delta) has been shown to improve insulin resistance, adiposity, and plasma HDL levels. However, its antiatherogenic role remains controversial. Here we report atheroprotective effects of PPAR delta activation in a model of angiotensin II (AngII)- accelerated atherosclerosis, characterized by increased vascular inf lammation related to repression of an antiinflammatory corepressor, B cell lymphoma-6 (Bcl-6), and the regulators of G protein-coupled signaling (RGS) proteins RGS4 and RGS5. In this model, administration of the PPAR delta agonist GW0742 (1or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery. In vitro studies demonstrated similar changes in AngII-treated macrophages: PPAR delta activation increased both total and free Bcl-6 levels and inhibited AngII activation of MAP kinases, p38, and ERK1/2. These studies uncover crucial proinflammatory mechanisms of AngII and highlight actions of PPAR delta activation to inhibit AngII signaling, which is atheroprotective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据